Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors

Qingyi Meng, Joao Lima, Hong Chen Lai, David Vlahov, David D Celentano, Steffanie A. Strathdee, Kenrad Edwin Nelson, Katherine Chih-Ching Wu, Shaoguang Chen, Wenjing Tong, Shenghan Lai

Research output: Contribution to journalArticle

Abstract

Background: Protease inhibitors (PIs) may be associated with accelerated atherosclerosis in individuals infected with human immunodeficiency virus (HIV). We assessed the effects of HIV PIs on subclinical atherosclerosis. Methods: The lipid profiles, C-reactive protein (CRP) levels, coronary artery calcification (CAC) scores, and blood cell morphologic changes were quantified in 98 black adult participants, aged 25 to 45 years, with HIV-1 infection in Baltimore, Md. Fifty-five participants (56.1%) were taking PIs; 43 participants (43.9%) were not. The Student t and x2 tests were used as a means of detecting the between-group differences. Results: Participants in both the PI and non-PI groups were similar in age, sex, body mass index, blood pressure, heart rate, and red and white blood cell counts. Compared with the non-PI group, the PI group had significantly higher serum total cholesterol (4.8 ± 1.0 vs 3.8 ± 0.7 mmol/L, P <.001) and LDL cholesterol (2.9 ± 0.8 vs 2.1 ± 0.7 mmol/L, P <.001) levels and red blood cell mean corpuscular volume (92.2 ± 9.3 vs 86.8 ± 7.2 μm3, P = .048). The CAC scores in the PI group were also higher than those in the non-PI group (11.0 ± 28.6 [n = 43] vs 1.7 ± 5.8, P = .043). CAC scores were marginally associated with log-transformed duration of the PI therapy (P = .055). Serum CRP levels remained unchanged (5.5 ± 13.6 mg/L [n = 45] vs 3.9 ± 5.5 mg/L, P = .467). Serum total cholesterol level, LDL cholesterol level, red blood cell mean corpuscular volume, and CAC scores were indicated by means of regression analyses to be associated with log-transformed duration of the PI therapy. Conclusions: The use of PIs is associated with coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in individuals infected with HIV-1.

Original languageEnglish (US)
Pages (from-to)642-648
Number of pages7
JournalAmerican Heart Journal
Volume144
Issue number4
DOIs
StatePublished - Oct 1 2002

Fingerprint

Erythrocyte Volume
Drug Users
Protease Inhibitors
HIV-1
Coronary Vessels
Lipids
Injections
Erythrocyte Indices
C-Reactive Protein
LDL Cholesterol
Atherosclerosis
Erythrocytes
Cholesterol
HIV
Baltimore
Erythrocyte Count
Virus Diseases
Serum
Leukocyte Count
Blood Proteins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{c0dae125dbba44c7b01e7480f8d6b203,
title = "Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors",
abstract = "Background: Protease inhibitors (PIs) may be associated with accelerated atherosclerosis in individuals infected with human immunodeficiency virus (HIV). We assessed the effects of HIV PIs on subclinical atherosclerosis. Methods: The lipid profiles, C-reactive protein (CRP) levels, coronary artery calcification (CAC) scores, and blood cell morphologic changes were quantified in 98 black adult participants, aged 25 to 45 years, with HIV-1 infection in Baltimore, Md. Fifty-five participants (56.1{\%}) were taking PIs; 43 participants (43.9{\%}) were not. The Student t and x2 tests were used as a means of detecting the between-group differences. Results: Participants in both the PI and non-PI groups were similar in age, sex, body mass index, blood pressure, heart rate, and red and white blood cell counts. Compared with the non-PI group, the PI group had significantly higher serum total cholesterol (4.8 ± 1.0 vs 3.8 ± 0.7 mmol/L, P <.001) and LDL cholesterol (2.9 ± 0.8 vs 2.1 ± 0.7 mmol/L, P <.001) levels and red blood cell mean corpuscular volume (92.2 ± 9.3 vs 86.8 ± 7.2 μm3, P = .048). The CAC scores in the PI group were also higher than those in the non-PI group (11.0 ± 28.6 [n = 43] vs 1.7 ± 5.8, P = .043). CAC scores were marginally associated with log-transformed duration of the PI therapy (P = .055). Serum CRP levels remained unchanged (5.5 ± 13.6 mg/L [n = 45] vs 3.9 ± 5.5 mg/L, P = .467). Serum total cholesterol level, LDL cholesterol level, red blood cell mean corpuscular volume, and CAC scores were indicated by means of regression analyses to be associated with log-transformed duration of the PI therapy. Conclusions: The use of PIs is associated with coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in individuals infected with HIV-1.",
author = "Qingyi Meng and Joao Lima and Lai, {Hong Chen} and David Vlahov and Celentano, {David D} and Strathdee, {Steffanie A.} and Nelson, {Kenrad Edwin} and Wu, {Katherine Chih-Ching} and Shaoguang Chen and Wenjing Tong and Shenghan Lai",
year = "2002",
month = "10",
day = "1",
doi = "10.1016/S0002-8703(02)00135-7",
language = "English (US)",
volume = "144",
pages = "642--648",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors

AU - Meng, Qingyi

AU - Lima, Joao

AU - Lai, Hong Chen

AU - Vlahov, David

AU - Celentano, David D

AU - Strathdee, Steffanie A.

AU - Nelson, Kenrad Edwin

AU - Wu, Katherine Chih-Ching

AU - Chen, Shaoguang

AU - Tong, Wenjing

AU - Lai, Shenghan

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Background: Protease inhibitors (PIs) may be associated with accelerated atherosclerosis in individuals infected with human immunodeficiency virus (HIV). We assessed the effects of HIV PIs on subclinical atherosclerosis. Methods: The lipid profiles, C-reactive protein (CRP) levels, coronary artery calcification (CAC) scores, and blood cell morphologic changes were quantified in 98 black adult participants, aged 25 to 45 years, with HIV-1 infection in Baltimore, Md. Fifty-five participants (56.1%) were taking PIs; 43 participants (43.9%) were not. The Student t and x2 tests were used as a means of detecting the between-group differences. Results: Participants in both the PI and non-PI groups were similar in age, sex, body mass index, blood pressure, heart rate, and red and white blood cell counts. Compared with the non-PI group, the PI group had significantly higher serum total cholesterol (4.8 ± 1.0 vs 3.8 ± 0.7 mmol/L, P <.001) and LDL cholesterol (2.9 ± 0.8 vs 2.1 ± 0.7 mmol/L, P <.001) levels and red blood cell mean corpuscular volume (92.2 ± 9.3 vs 86.8 ± 7.2 μm3, P = .048). The CAC scores in the PI group were also higher than those in the non-PI group (11.0 ± 28.6 [n = 43] vs 1.7 ± 5.8, P = .043). CAC scores were marginally associated with log-transformed duration of the PI therapy (P = .055). Serum CRP levels remained unchanged (5.5 ± 13.6 mg/L [n = 45] vs 3.9 ± 5.5 mg/L, P = .467). Serum total cholesterol level, LDL cholesterol level, red blood cell mean corpuscular volume, and CAC scores were indicated by means of regression analyses to be associated with log-transformed duration of the PI therapy. Conclusions: The use of PIs is associated with coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in individuals infected with HIV-1.

AB - Background: Protease inhibitors (PIs) may be associated with accelerated atherosclerosis in individuals infected with human immunodeficiency virus (HIV). We assessed the effects of HIV PIs on subclinical atherosclerosis. Methods: The lipid profiles, C-reactive protein (CRP) levels, coronary artery calcification (CAC) scores, and blood cell morphologic changes were quantified in 98 black adult participants, aged 25 to 45 years, with HIV-1 infection in Baltimore, Md. Fifty-five participants (56.1%) were taking PIs; 43 participants (43.9%) were not. The Student t and x2 tests were used as a means of detecting the between-group differences. Results: Participants in both the PI and non-PI groups were similar in age, sex, body mass index, blood pressure, heart rate, and red and white blood cell counts. Compared with the non-PI group, the PI group had significantly higher serum total cholesterol (4.8 ± 1.0 vs 3.8 ± 0.7 mmol/L, P <.001) and LDL cholesterol (2.9 ± 0.8 vs 2.1 ± 0.7 mmol/L, P <.001) levels and red blood cell mean corpuscular volume (92.2 ± 9.3 vs 86.8 ± 7.2 μm3, P = .048). The CAC scores in the PI group were also higher than those in the non-PI group (11.0 ± 28.6 [n = 43] vs 1.7 ± 5.8, P = .043). CAC scores were marginally associated with log-transformed duration of the PI therapy (P = .055). Serum CRP levels remained unchanged (5.5 ± 13.6 mg/L [n = 45] vs 3.9 ± 5.5 mg/L, P = .467). Serum total cholesterol level, LDL cholesterol level, red blood cell mean corpuscular volume, and CAC scores were indicated by means of regression analyses to be associated with log-transformed duration of the PI therapy. Conclusions: The use of PIs is associated with coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in individuals infected with HIV-1.

UR - http://www.scopus.com/inward/record.url?scp=0036791190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036791190&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(02)00135-7

DO - 10.1016/S0002-8703(02)00135-7

M3 - Article

VL - 144

SP - 642

EP - 648

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -